Randomized, crossover, two-period, two-treatment, comparative bioavailability study of ibuprofen (arginine) granules for oral solution, developed by Farmalider, S.A., and Espidifen® granules for oral solution, administered in single dose of 600 mg to healthy subjects under fasting conditions.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509219-97-00

Acronym

FMLD- IO600-58-1

Enrollment

Registered

2024-03-20

Start date

2024-04-01

Completion date

2024-05-17

Last updated

2024-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026